Product Description
Lactobacillus paracasei to reduce the GI and psychological symptoms of IBS
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Nondrug
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: KGK Science
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Irritable Bowel Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 14PIHL | P2 |
Completed |
Irritable Bowel Syndrome |
2018-02-15 |
22% |